Introduction
The 2007 guidelines from the European Society of Hypertension and the European Society of Cardiology (ESH/ ESC) [1] as well as the seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC7) [2] have recognized the following measures of chronic kidney disease as risk factors for cardiovascular morbidity and mortality: the presence of microalbuminuria [defined as a persistent elevation of urinary albumin-to-creatinine ratio (UACR) in the range 30-299 mg/g] and an estimated glomerular filtration rate (GFR) less than 60 ml/min/1.73 m 2 . Even a GFR greater than or equal to 60 ml/min/1.73 m 2 may be indicative of subclinical organ damage in the presence of microalbuminuria [1] . The presence of microalbuminuria is relatively cheap and easy to determine [1] . Although the American Diabetes Association [3] and JNC7 [2] recommend the monitoring of patients with diabetes for microalbuminuria, screening of the general population is not routinely undertaken [4] . The degree of microalbuminuria directly correlates with the incidence of cardiovascular disease, as will be discussed in detail in this article. Therefore, the early identification and treatment of microalbuminuria has important public health implications, because without effective management, the eventual need for specialist healthcare will prove very costly [5] .
Evidence for the correlation of cardiovascular risk and renal function
Although there are many studies suggesting that a decline in renal function and the presence of proteinuria correlates with an increased likelihood of cardiovascular disease [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] , the most conclusive evidence comes from the study by Go et al. [16] , who demonstrated a direct relationship between the extent of the decline in renal function and incidence of cardiovascular events. Using a database of 1 120 295 adults who had not undergone dialysis or kidney transplantation and in whom the serum creatinine had been measured between 1996 and 2000, the estimated GFR was determined and subsequently correlated with the incidence of all-cause death, cardiovascular events, and any hospitalization over a median follow-up of 2.8 years. After adjusting for confounding factors (age, sex, education, use or nonuse of dialysis, and the presence or absence of prior coronary heart disease, heart failure, ischemic stroke or transient ischemic attack, peripheral artery disease, type 2 diabetes, hypertension, dyslipidemia, cancer, serum albumin 3.5 g/dl, cirrhosis or chronic liver disease, chronic lung disease, documented proteinuria, and prior hospitalization), hazard ratios were determined according to estimated GFR of 45-59, 30-44, 15-29 , and less than 15 ml/min/1.73 m 2 in relation to a hazard ratio of 1 for an estimated GFR of more than 60 ml/min/1.73 m 2 . Even at early stage 3 nephropathy (i.e., estimated GFR 45-59 ml/min/ 1.73 m 2 ), the adjusted hazard ratio for any cardiovascular event was increased (Table 1) , and the hazard ratio increased further still with further falls in estimated GFR. There was also an independent and graded association between estimated GFR and all-cause mortality and any hospitalization.
Importance of microalbuminuria as predictor of cardiorenal endpoints
The presence of microalbuminuria provides evidence that there is an inflammatory process taking place in the kidney and an endothelial dysfunction. Because similar changes can take place simultaneously in the general vasculature, microalbuminuria is thus a powerful predictor of cardiovascular disease [17] . The prognostic value of microalbuminuria has been shown to be superior to that of C-reactive protein. In a prospective community study, the 5-year follow-up of 626 elderly patients without cardiac or renal failure who provided serum and urine samples found that, after adjustment for age, sex, smoking, diabetes mellitus, hypertension or ischemic heart disease, total cholesterol, and serum creatinine, the hazard ratio [95% confidence interval (CI)] for mortality for values above the 80th percentile for the UACR was 1.9 (1.2-3.0) [18] . This compared with ratios of 2.0 (1.2-3.2), and 1.5 (0.9-2.2) for the corresponding values for serum N-amino terminal fragment of the prohormone brain natriuretic peptide (BNP) and C-reactive protein, respectively. In the case of first major cardiovascular event (i.e., nonfatal myocardial infarction, fatal coronary heart disease, unstable angina, heart failure, stroke, or transient ischemic attack), the hazard ratios were 2.3 (1.3-4.1), 3.2 (1. 8-5.8) , and 1.0 (0.6-1.9) for microalbuminuria, BNP, and C-reactive protein, respectively. A study in 4421 Chinese patients with type 2 diabetes has shown that, even in patients with what is generally regarded as a clinically normal estimated GFR of more than 90 ml/min/1.73 m 2 , the risk of a cardiovascular event (ischemic heart disease, congestive heart failure, stroke, or revascularization procedure) was increased by 85% and risk of a renal endpoint (estimated GFR declining by >50% or progression to estimated GFR <15 ml/min/ 1.73 m 2 , or renal dialysis or death secondary to renal causes) rose by 162% over a median follow-up period of 39.4 months if the UACR was 300 mg/g or more [19] . For an estimated GFR of 39-59 ml/min/1.73 m 2 , the presence of microalbuminuria or macroalbuminuria resulted in only a 35% increase in the risk of cardiovascular event, whereas the risk of a renal endpoint was increased 10.27-fold. This study, therefore, shows that early renal damage is more likely to result in cardiovascular events, and only when chronic kidney disease becomes well established, with the loss of approximately half of renal function, is the risk of a renal endpoint greater than that for a cardiovascular event.
Evidence that reducing microalbuminuria confers cardiovascular benefit
There are currently no prospective data to show that, independent of blood pressure control, a reduction in microalbuminuria results in a lower incidence of cardiovascular events. However, there are retrospective data to support the hypothesis that early renoprotection lowers cardiovascular risk, one example being a posthoc analysis from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study [20] . Over the 4.8-year period of this double-blind study, despite similar reductions in office blood pressure in the atenolol-based and losartan-based treatment groups, greater median annual changes in UACR were observed in those patients who had received the angiotensin II receptor blocker (ARB) based therapy ( Fig. 1 ). This retrospective analysis showed that at year 2, the reduction in UACR was 33% with losartan compared with 25% with atenolol. The primary results of LIFE demonstrated that the patients, who all had left ventricular hypertrophy, receiving losartan were those who experienced greater cardiovascular benefit: the relative risk of the cardiovascular morbidity and mortality was 0.87 compared with atenolol [21] .
In addition, the posthoc analysis from the Reduction in ENdpoints in noninsulin-dependent diabetes mellitus with the Angiotensin Antagonist Losartan (RENAAL) GFR, glomerular filtration rate. Reproduced with permission from [16] .
Fig. 1
Effects of losartan compared with atenolol on annual median changes from baseline in urinary albumin-to-creatinine ratio. UACR, urinary albumin-to-creatinine ratio. Reproduced with permission from [20] .
study showed that the risk of end-stage renal disease had a clear dependence on albuminuria reduction, regardless of change in SBP. At month 6 from baseline, the hazard ratio for albuminuria reduction was 3.42 (2.45-4.77) versus 1.22 (0.89-1.68) in SBP reduction. The combination of the reduction in both albuminuria and SBP results in a most favorable clinical outcome in hypertensive patients with diabetic nephropathy [22] .
Furthermore, in a follow-up study of 3.1 years, in hypertensive patients with nondiabetic renal disease with a urinary protein excretion more than 1 g/day despite treatment with angiotensin-converting enzyme (ACE) inhibitor, it was demonstrated that the ARB candesartan, added on the background of ACE inhibitor therapy, provided a better decrease in urinary protein excretion and slowing of renal function deterioration. In particular, at year 3, the serum creatinine concentration was increased from 3.02 AE 0.27 to 3.38 AE 0.49 mg/dl in the candesartan and ACE inhibitor group versus 3.00 AE 0.37 to 4.48 AE 0.57 mg/dl in the ACE inhibitor group (P < 0.01). The level of proteinuria significantly declined in each group (P < 0.05); however, the degree of reduction in proteinuria was greater in the candesartan group than in the ACE inhibitor group (P < 0.01) [23] .
These data, taken together with a recent review [24] , strongly support the concept that blood pressure reduction without proteinuria reduction in advanced nephropathy fails to provide maximal protection against a decline in kidney function. This association is true regardless of whether the cause of nephropathy is related to diabetic or nondiabetic causes [25] . Lastly, although it is clear that further reducing proteinuria by combining an ACE inhibitor with an ARB should translate into further slowing of nephropathy, unfortunately there are no prospectively designed outcome trials to address this issue [26] .
Prevention of chronic kidney disease progression
There have been numerous prospective outcomes trials that have demonstrated differences in renal outcomes in patients without diabetes according to treatment, but all enrolled patients had clinically significant (stage 3) renal impairment, with baseline GFR ranging between 26 and 40 ml/min/1.73 m 2 [27] [28] [29] [30] [31] . Similarly, the studies in patients with diabetes were also performed in patients with overt nephropathy (GFR 58-68 ml/min/1.73 m 2 ) at baseline [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] . The one exception is the Appropriate Blood pressure Control in Diabetes (ABCD) study, in which patients with type 2 diabetes displayed normoalbuminuria or microalbuminuria [38] . This study showed that the effects of nisoldipine or enalapril as the initial antihypertensive medication on the progression of chronic kidney disease over a 5-year period did not differ. Overall, therefore, the findings of these studies suggest that the targeting of the renin-angiotensin system using either an ACE inhibitor [28] [29] [30] [31] [32] [33] [34] or an ARB [36, 37] is only beneficial in patients with overt nephropathy and the loss of approximately half of the renal function. This is despite evidence that angiotensin II acts pathophysiologically throughout the renal continuum.
The importance of controlling proteinuria
Studies have consistently demonstrated that early changes in proteinuria predict longer-term renal outcomes both in patients without diabetes [39] and those with diabetes [40, 41] .
In the African-American Study of Kidney disease and hypertension (AASK) conducted in 1094 patients without diabetes who were followed for a median of 3.8 years, there was a direct relationship between the change in proteinuria after starting antihypertensive treatment (metoprolol, ramipril, or amlodipine) and the relative risk of end-stage renal disease (Fig. 2) [39] . The patients treated with amlodipine were the ones with the greatest increase in proteinuria and the highest incidence of endstage renal disease. This observation could not be attributed to poorer control of blood pressure using this calcium channel blocker, which has displayed comparable antihypertensive activity to that of lisinopril.
The data from the RENAAL study showed that changes in proteinuria in the first 6 months of therapy were linearly related to the degree of long-term renal protection [40] . For every 50% reduction in proteinuria at 6 months, risks of the composite renal endpoint (doubling of serum creatinine, end-stage renal disease, or death) or end-stage renal disease occurring were reduced by 36 and 45%, respectively, at the 48-month follow-up.
Similarly, Kaplan-Meier analysis of the follow-up data from the Irbesartan in Diabetic Nephropathy Trial
ARBs for cardiovascular protection Kalaitzidis and Bakris S17 Fig. 2 Association of the risk of end-stage renal disease with the change in urinary protein-to-creatinine ratio from baseline to 6 months, controlled for randomized treatment group and the initial level of proteinuria. ESRD, end-stage renal disease; UPCR, urinary protein-to-creatinine ratio. Reproduced with permission from [39] .
(IDNT) showed that the percentage change in proteinuria after 1 year of treatment predicted the time to a renal endpoint (Fig. 3) [41] . For each halving of the proteinuria level between baseline and 12 months' treatment, the hazard ratio was 0.44 (95% CI 0.40-0.49; P < 0.001).
These observations have also been described in studies of nondiabetic renal disease [39] .
The effect of sodium intake on proteinuria
A diet high in sodium chloride appears to militate against the antiproteinuric benefit of renin-angiotensin system blockade [42] . In 12 patients with proteinuria and high blood pressure, lisinopril 5-10 mg brought about a dosedependent reduction in proteinuria. When the patients' salt intake was increased from 50 to 200 mmol/day, the antiproteinuric effect of lisinopril was reduced, but it recovered when a sodium-restricted diet was reintroduced. It has been calculated that, if salt intake exceeds 4 g/day, the efficacy of lisinopril can be reduced by up to 50% [42] . If a thiazide diuretic is given in addition to an ACE inhibitor, the deleterious effect of a high salt intake can be blunted, but the antiproteinuric activity is only restored by about half [43] . However, on this basis, recent reports emphasize the fact that combined interventions in sodium status is an effective method to maximize the antiproteinuric efficacy of RAS blockade [46, 47] .
The mechanism by which salt reduces the antiproteinuric effect of renin-angiotensin system blockade has yet to be firmly established. Increased blood pressure is a partial explanation [44] . High salt intake impairs endotheliumdependent dilatation though reduced nitric oxide bioavailability [48] . Oxidative stress has also been implicated, based on a study in salt-sensitive and salt-resistant hypertensive patients [45] . Levels of total and lipidbound isoprostanes increased with salt loading and then decreased with salt depletion, the effects being most marked in the salt-sensitive persons. Correlations between changes in lipid-bound isoprostanes and plasma renin activity and aldosterone-to-renin ratios with salt depletion suggest that the reduction of oxidative stress by salt depletion is greater in more salt-sensitive persons.
The effect of telmisartan on renal function
In a multicenter, prospective, double-blind, forcedtitration, randomized study in 96 patients with type 2 diabetes, hypertension, GFR more than 80 ml/min and normoalbuminuria or microalbuminuria blockade of the renin-angiotensin system with telmisartan 40/80 mg, and ramipril 5/10 mg for 9 weeks, it was shown that telmisartan and ramipril both increased nitric oxide activity of the endothelium significantly, which in turn may support the preservation of cardiovascular and renal function [49] .
In the multicenter, double-blind, placebo-controlled INcipieNt to OVert: Angiotensin II blocker, Telmisartan, Investigation On type 2 diabetic Nephropathy (INNOVATION) study, which was performed in 527 normotensive or hypertensive Japanese persons with microalbuminuria, the effects of two doses of telmisartan (40 or 80 mg/day) were evaluated for the prevention of the transition from microalbuminuria to overt nephropathy (UACR >300 mg/g) over a mean period of 1.3 years [50] . With either dose of telmisartan, transition rates to overt nephropathy were lower than with placebo in the overall patient population (Fig. 4) : telmisartan 80 mg (n ¼ 168) 16.7%; telmisartan 40 mg (n ¼ 172) 22.6%; and placebo (n ¼ 174) 49.9% (both telmisartan doses versus placebo, P < 0.0001). Telmisartan was also superior to placebo in bringing about remission to normoalbuminuria: telmisartan 80 mg 21.2%; telmisartan 40 mg S18 Journal of Hypertension 2009, Vol 27 (suppl 5) Fig. 3 Kaplan-Meier plot of time to a renal endpoint according to the change in proteinuria from baseline after the receipt of treatment for 12 months. ESRD, end-stage renal disease. Adapted with permission from [41] . Kaplan-Meier plots for the transition from incipient to overt nephropathy in patients treated once daily with telmisartan 80 mg (T80), telmisartan 40 mg (T40), or placebo. Reproduced with permission from [50] .
12.8%; and placebo 1.2% (both telmisartan doses versus placebo; P < 0.001). An additional finding of this study was that telmisartan dose-dependently reduced the incidence of the transition to overt nephropathy in normotensive patients with microalbuminuria. This suggests that telmisartan had an effect on renal function that was independent of its antihypertensive effect. Further evidence to support this conclusion is that differences in transition rates with telmisartan were maintained when adjustment was made for the telmisartan-induced reduction in SBP.
Another study -A comparison of telMisartan versus losArtan in hypertensive type 2 DiabEtic patients with Overt nephropathy (AMADEO) [51] -was designed to determine whether pharmacological differences between telmisartan and losartan would translate into larger and more durable reductions in proteinuria over time. Compared with losartan (an ARB already approved for diabetic nephropathy to prevent renal disease progression), the highly lipophilic ARB telmisartan has a longer halflife (approximately 24 h compared with 6-9 h for EXP 3174, the prodrug of losartan) and displays approximately 25% greater angiotensin II type 1 receptor binding [52] . The multicenter, double-blind, prospective study was performed in 860 hypertensive (SBP/DBP >130/ 80 mmHg or receiving antihypertensive medication at baseline) patients with type 2 diabetes and who had a morning spot urinary protein-to-creatinine ratio 700 mg/g or more. After a placebo run-in period, the randomized patients received either telmisartan 40 mg or losartan 50 mg for 2 weeks, followed by telmisartan 80 mg or losartan 100 mg, respectively, for 50 weeks.
The magnitude of the reduction in proteinuria expressed as UACR at 52 weeks -the primary endpoint -was significantly greater with telmisartan (29.8%) compared with losartan (21.4%; P ¼ 0.027) (Fig. 5) [51] . Differences in the antiproteinuric effects of the two angiotensin II receptors blockers could not be attributed to their effects on blood pressure: mean SBP and DBP reductions were not significantly different (P ¼ 0.06 and P ¼ 0.61, respectively) between groups at the end of the study. Also, no difference was detected between the treatment groups in urinary sodium excretion.
Treatment of patients with chronic kidney disease
The same principles apply irrespective of whether or not the patient has diabetes, with the aim being to reduce blood pressure to less than 130/80 mmHg. In patients with chronic kidney disease (defined as an estimated GFR !50 ml/min/1.73 m 2 ) and any degree of microalbuminuria, ARB or ACE inhibitor therapy should be initiated, with uptitration to the maximum approved dose if blood pressure is less than 20 mmHg above the goal. If blood pressure is 20 mmHg or more, it is probably appropriate for the ARB or ACE inhibitor to be given in combination with a calcium channel blocker or a longacting thiazide diuretic. The choice of additional therapy, such as the addition of an aldosterone receptor blocker or a vasodilator, may vary according to the presence of obesity and hyperkalemia.
Data from the ONTARGET study suggest that telmisartan is as good as the ACE inhibitor ramipril for slowing progression of kidney disease, as there were no differences in people who progressed to end-stage renal disease [53] .
Conclusion
All patients with proteinuria, irrespective of whether they have microalbuminuria or overt nephropathy, and blood pressure more than 130/80 mmHg must be aggressively treated to prevent cardiovascular morbidity and mortality and avoid end-stage renal disease, which requires kidney transplantation or dialysis to ensure survival. There is substantive evidence for the beneficial effects of the pharmacological targeting of the renin-angiotensin system, using an ACE inhibitor or an ARB in patients with or without diabetes. Recent clinical evidence shows that telmisartan confers renoprotection in patients with or without diabetes and either microalbuminuria or overt nephropathy. This renoprotective effect may be partly attributed to the control of blood pressure, but there are data to suggest that telmisartan may have protective effects on the kidney that are independent of blood pressure.. ARBs for cardiovascular protection Kalaitzidis and Bakris S19 Effect of telmisartan 80 mg and losartan 100 mg on urinary protein-tocreatinine in patients with type diabetes and overt nephropathy. UPC, urinary protein-to-creatinine. Reproduced with permission from [51] .
